The first ever citation screening challenge is almost under way!
Starting at 10:00 GMT on Friday 31st October and running for 48 hours, around 75 EMBASE project screeners are working their way through as many citations as they can in an effort to identify reports of randomised trials.
As far as we know this is the first challenge of this kind and what makes it all the more special is that for every citation screened, 5p will be donated to Médecins Sans Frontières (MSF) for the Ebola relief effort.External link for more information: http://www.metaxis.com/EmbaseChallenge Contributor's Information Contributor's name: Anna Noel-Storr Email address: email@example.com
Strictly Embargoed Until 00.01 Hours (GMT), Thursday, October 30, 2014
[20.01 Hours US Eastern Time (EDT), October 29 /11.01 Hours Australian Eastern Daylight Time (AEDT), October 30]
It seems to me that what is missing is the views of parents and partners of patients who can give their take on what the patients are reporting. Only then will the true picture of the situation of people with psychosis be available, as patient views would be ratified - or contradicted - by those involved in their care long-term.
Our son started experimenting with cannabis when he was fourteen and we feel strongly that this contributed to his developing schizophrenia from about the age of seventeen. It became apparent during his prolonged stay in a psychiatric unit under a section that he was also treatment resistant. Only when he was treated with clozapine which had to be augmented did he begin to stabilise.
The doctor treating him felt that he, in his practice, was seeing more young men like this and he felt that the brain being bathed in these illicit drugs during adolescence was a contributory factor.
Our son managed to procure cannabis whilst in hospital under section and was cautioned and fined for this despite at the time not being deemed fit to make decisions. Fortunately he now no longer smokes cannabis but has to take medication and lives in supported accommodation. He is now 23 years old and is just beginning to have a life again.
I believe that all mind altering drugs are harmful. The ideal psychiatric system would be Open Dialogue, a non-invasive method with a very minimal use of drugs. ANY mind altering drug is just a short cut, panic measure, which might work for a short time, but with unpredictable and often very disastrous long-term effects.
Schizophrenia is a serious mental illness and is usually treated using antipsychotic medication. However, although effective, antipsychotic medication can cause side-effects (such as sleepiness, weight gain and even dribbling). Acupuncture has been shown to have very few negative effects on the individual and could be more socially acceptable and tolerable for people with mental health problems. Acupuncture may also be less expensive than drugs made by pharmaceutical companies, so reducing costs to individuals and health services.
This reviews looks at the effectiveness of various types of acupuncture as treatment for people with schizophrenia. An update search for studies was carried out in 2012 and found 30 studies that randomised participants who were receiving antipsychotic medication to receive additional acupuncture or standard care.
Although some of the studies did favour acupuncture when combined with antipsychotics, the information available was small scale and rated to be very low or low quality by the review authors, so not completely provable and valid. Depression was reduced when combining acupuncture with antipsychotic medication, but again this finding came from small-scale research, so cannot be clearly shown to be true. The review concludes that people with mental health problems, policy makers and health professionals need much better evidence in order to establish if there are any potential benefits to acupuncture.
This means that the question of whether acupuncture is of benefit to people, and whether it is of greater benefit than antipsychotic medication, remains unanswered. There is not enough information to establish that acupuncture is of benefit or harm to people with mental health problems.
See more at: http://summaries.cochrane.org/CD005475/SCHIZ_acupuncture-for-schizophrenia
The results of the review are limited as trial sizes were small and data were poorly reported.
Overall, there is currently no evidence for any intervention, whether it is psychological therapy or medication, being better than standard treatment or each other in reducing or stopping the use of cannabis. More research is needed to explore the benefits of medication or psychological therapy for those with schizophrenia who use cannabis. It is unclear if cannabidiol has an antipsychotic effect.
See more at: http://summaries.cochrane.org/CD004837/SCHIZ_cannabis-for-schizophrenia
It is with great sadness that The Cochrane Collaboration announces the death of our colleague and friend, Monica Kjeldstrøm, on Sunday, 19 October 2014. Our thoughts and condolences are with Monica’s family, friends, and colleagues in Denmark and around the world.Contributor's Information Contributor's name: Cochrane CEAD Email address: firstname.lastname@example.org
Nine positions on the Cochrane Steering Group (CSG), including one Co-Chair, were eligible for election in 2014.
Representing Authors: Mona Nasser (UK) – re-elected for a second term from September 2014 – September 2017 (this result was also announced on 24 June 2014).
Representing Centre Directors: Alvaro Atallah (Brazil) – elected for his first term from September 2014 – September 2017.
Representing Centre Staff: Joerg Meerpohl (Germany) - elected for his first term from September 2014 - September 2017.External link for more information: http://www.cochrane.org/community/organisation-administ... Contributor's Information Contributor's name: Claire Allen Email address: email@example.com
Bobby Ramakant and Shobha Shukla of India's Citizen News Service were among the journalists invited to attend the 2014 Cochrane Colloquium in Hyderabad in September. Both entered fully into the Colloquium experience, participating in symposia and workshops, as well as attending a variety of sessions, conducting interviews with more than a dozen Colloquium delegates, and writing an extensive series of articles on topics relevant to the main theme of the 22nd Colloquium, 'Evidence-informed Public Health'.External link for more information: http://www.citizen-news.org/ Contributor's Information Contributor's name: Cochrane CEAD Email address: firstname.lastname@example.org
Several prizes are awarded annually to Cochrane contributors. The 2014 recipients, awarded at the Hyderabad Colloquium, are as follows:External link for more information: http://www.cochrane.org/about-us/awards-scholarships-fu... Contributor's Information Contributor's name: Cochrane CEAD Email address: email@example.com
In March 2014, Cochrane circulated a Request for Proposals inviting submissions for the development, installation, and support of a multifaceted technology platform to support Cochrane authors in producing and maintaining Cochrane Reviews.Contributor's Information Contributor's name: Cochrane IKMD Email address: firstname.lastname@example.org
Cochrane is delighted to announce the official opening of a new Cochrane branch in Hungary.
The establishment of the Hungarian branch, part of the Cochrane German Centre, will have its base at the University of Pécs.
The branch will promote evidence-informed decision making in health care by producing accurate, up-to-date Cochrane Reviews, as well as providing support and training to new Cochrane Review authors.
The Director of the Hungarian Branch is Professor Tamás Decsi who is a professor of paediatrics and Director of the Clinical Centre of the University of Pécs.External link for more information: http://www.cochrane.de Contributor's Information Contributor's name: Cochrane CEAD Email address: email@example.com
Are you a Cochrane author? Are you active on Twitter? Please join us for the October edition of the #cochraneauthor Twitter chat, to be guest hosted by Cochrane's Senior Training Co-ordinator, Miranda Cumpston.External link for more information: http://www.cochrane.org/training Contributor's Information Contributor's name: Cochrane CEAD Email address: firstname.lastname@example.org
Cochrane Depression, Anxiety and Neurosis Group supports launch of priority-setting initiative for bipolar research in the UK
A new UK-wide survey about bipolar has been launched by a partnership of mental health groups, supported by the Cochrane Depression, Anxiety, and Neurosis Group.
The survey gives individuals, families, clinicians and other professionals the opportunity to influence research into the causes, diagnosis, treatment and care of bipolar.
The survey has been developed by the James Lind Alliance Bipolar Priority Setting Partnership (PSP) with partners including charities, research funders, clinicians and service users.External link for more information: http://www.ouh.nhs.uk/bipolar Contributor's Information Contributor's name: Jessica Sharp Email address: email@example.com